CompletedEUCTR 2021-002572-39
Effects of add-on Celecoxib treatment in patients with schizophrenia spectrum disorders and inflammatory cytokine profile (TargetFlame)
This historical record does not confirm current site availability.
Historical research recordGermany
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with schizophrenia. Other eligibility criteria applied.
- Listed locations
- Germany
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Bezirkskliniken Schwaben
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Germany
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2021-002572-39
- Official title
Show the full official title
Effects of add-on Celecoxib treatment in patients with schizophrenia spectrum disorders and inflammatory cytokine profile (TargetFlame)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Germany
Registry details
Historical country statuses
- Germany — Completed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Bezirkskliniken Schwaben.
Who was this study for?
This study was for people with schizophrenia. Other eligibility criteria applied.
